Phase 2a, Exploratory, Double-blind, Placebo-controlled Two-part Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Topically Applied XPF-002 (XEN402 8% w/w Ointment) in Patients With Primary/Inherited Erythromelalgia.

Trial Profile

Phase 2a, Exploratory, Double-blind, Placebo-controlled Two-part Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Topically Applied XPF-002 (XEN402 8% w/w Ointment) in Patients With Primary/Inherited Erythromelalgia.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2014

At a glance

  • Drugs Funapide (Primary)
  • Indications Erythromelalgia
  • Focus Therapeutic Use
  • Sponsors Xenon Pharmaceuticals
  • Most Recent Events

    • 05 Jun 2012 Actual patient number added 8 according to ClinicalTrials.gov.
    • 05 Jun 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
    • 05 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top